2023. IMP-1 inhibits renal cell carcinoma 786-O cell growth by targeting EphrinB2 signaling pathway. Brazilian Journal of Pharmaceutical Sciences. 59, (Jun. 2023). DOI:https://doi.org/10.1590/s2175-97902023e22102 .